SecBot SecBot
144 ·Filed May 28, 2026

ETON

Eton Pharmaceuticals, Inc.
BEARISH
Impact 5/10
Horizondays Processed5mo ago SEC0001949846-26-000326
Form 144 — notice of proposed sale of securities
Actionable Insight ▼ Bearish

CEO's intent to sell a meaningful stake ahead of any upcoming catalysts warrants monitoring. While the sale is not yet executed, the filing signals insider desire to monetize. Watch for actual Form 4 filings and any upcoming earnings or pipeline updates that could explain the timing.

DirectionBearish
Confidencemedium
Horizondays
Final — all horizons settled through T+60d
ETON ▲ +99.22% at T+60d
SHORT call ✗ call lost -99.22% · α vs SPY -97.48% · entry $31.86 → $63.47
Entry = T+0 close
May 28, 2026
via day close
T+1d
-4.43%
call +4.43% · α +4.67%
$30.45
settled 5mo ago
T+5d
-13.34%
call +13.34% · α +13.29%
$27.61
settled 5mo ago
T+20d
+12.05%
call -12.05% · α -15.20%
$35.70
settled 4mo ago
T+60d
+99.22%
call -99.22% · α -97.48%
$63.47
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

CEO Sean Brynjelsen filed a Form 144 indicating intent to sell 120,000 common shares valued at approximately $3.89 million, representing about 0.44% of the company's $888M market cap. The shares were acquired as founder shares and open-market purchases, and the sale is planned through a broker at current market prices.

Key Facts

  • CEO Sean Brynjelsen filed Form 144 to sell 120,000 shares
  • Estimated proceeds: ~$3.89 million at $32.40/share
  • Shares acquired as founder shares and open-market purchases dating back to 2017
  • Sale represents ~0.44% of $888M market cap
  • Recent insider activity: 3 sells totaling $2.9M in past 30 days

Financial Impact

CEO plans to sell ~$3.89M in stock, a notable insider sale relative to recent insider activity of $2.9M in prior 30 days

insider sellingdilution

Risk Factors

  • CEO selling may signal lack of confidence in near-term prospects
  • Potential overhang if sale is executed over time
  • Recent insider selling cluster (3 sells, $2.9M in 30 days) amplifies concern

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001949846-26-000326
Document: 0001949846-26-000326-index.html0001949846-26-000326
Document: 0001949846-26-000326.txt0001949846-26-000326
23 reports for ETON
Performance horizon
86% Hit rate @ T+60 6 of 7 directional calls Went positive at some point 12 of 13 best @ T+60▲ +95.18%Feb 25, 2026
Filters
Rows
Reports for ETON — sortable, filterable
TypeNow
Oct 14, 2026
13d ago
8-K
BULLISH ★ 6/10
$52.88awaiting T+60—$51.16 (−3.25%)
Oct 6, 2026
21d ago
144
NEUTRAL ★ 2/10
$54.88awaiting T+60—$51.16 (−6.78%)
Sep 28, 2026
29d ago
8-K
BULLISH ★ 5/10
$59.18awaiting T+60—$51.16 (−13.55%)
Aug 31, 2026
8w ago
Insider Cluster
NEUTRAL ★ 4/10
$60.43awaiting T+60—$51.16 (−15.34%)
Aug 28, 2026
8w ago
Insider Cluster
NEUTRAL ★ 4/10
$60.44awaiting T+60—$51.16 (−15.35%)
Aug 24, 2026
9w ago
Insider Cluster
BEARISH ★ 5/10
$63.05awaiting T+60—$51.16 (+18.86%)
Aug 19, 2026
9w ago
144
BEARISH ★ 5/10
$61.48awaiting T+60—$51.16 (+16.79%)
Aug 5, 2026
11w ago
8-K
BULLISH ★ 6/10
$45.97awaiting T+60—$51.16 (+11.29%)
Aug 5, 2026
11w ago
Press Release
BULLISH ★ 7/10
$45.97awaiting T+60—$51.16 (+11.29%)
Aug 4, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$45.83awaiting T+60—$51.16 (+11.63%)
Showing 10 of 23

US Market Status

Market Closed — Opens Wed (17h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 28, 2026